Exagen Inc. (XGN)
NASDAQ: XGN
· Real-Time Price · USD
6.43
0.18 (2.88%)
At close: May 06, 2025, 3:59 PM
6.37
-0.93%
After-hours: May 06, 2025, 04:08 PM EDT
2.88% (1D)
| Bid | 5.95 |
| Market Cap | 115.08M |
| Revenue (ttm) | 56.72M |
| Net Income (ttm) | -15.51M |
| EPS (ttm) | -0.83 |
| PE Ratio (ttm) | -7.75 |
| Forward PE | -19.27 |
| Analyst | Strong Buy |
| Ask | 7 |
| Volume | 321,987 |
| Avg. Volume (20D) | 116,150 |
| Open | 6.18 |
| Previous Close | 6.25 |
| Day's Range | 6.17 - 6.76 |
| 52-Week Range | 1.35 - 7.00 |
| Beta | 1.51 |
About XGN
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables diff...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Sep 19, 2019
Employees 209
Stock Exchange NASDAQ
Ticker Symbol XGN
Website https://www.exagen.com
Analyst Forecast
According to 2 analyst ratings, the average rating for XGN stock is "Strong Buy." The 12-month stock price forecast is $7.5, which is an increase of 16.64% from the latest price.
Stock ForecastsEarnings Surprise
Exagen has released their quartely earnings
on May 5, 2025:
9 months ago
+12.65%
Exagen shares are trading higher after the company...
Unlock content with
Pro Subscription
